Elliot Goldstein, President and CEO of ProMIS Neurosciences shares this company’s objective of looking for treatments and cures for Alzheimer’s disease.
Projections from the Alzheimer’s Association 2013 show that the direct and indirect medical costs of Alzheimer’s disease with over 500 billion US dollars expected to triple by 2025. This will bankrupt our healthcare systems. ProMIS Neurosciences is focused exclusively looking for treatments and cures for Alzheimer’s disease.
Using our proprietary techniques, we were able to identify toxic proteins and create five products that specifically target those toxic proteins. There’s a very interesting phenomenon going on and we’re right at the forefront of that. Modern bioscience now is coming together with… we’ll call it big data engineering IT etc. And now we can look at these toxic molecules these bad actors that destroy cells at a very, very detailed and fine level. This was never possible before. So we use these the proprietary algorithms if you like, these are very complex equations on supercomputers to identify very specific and selective targets to aim our drugs at.
So we know that they bind to the bad actor, now we just need to show that they knock him out. And we’re the process of doing that, both in vitro which means in the lab in Petra dishes, but also in animal studies. Hope for this company – it’s actually a hope for, a societal hope and that’s really to make it as a clear contribution to solving the problem of Alzheimer’s disease.
For more information on ProMIS Neurosciences (PMN:TSX) and their treatment for Alzheimer’s disease, fill out the form below.